Sidley is representing Denali Capital Acquisition Corp. (Denali) (NASDAQ: DECA), a publicly traded special purpose acquisition company, in its pending business combination with Longevity Biomedical, Inc. (Longevity), a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring, and digital health solutions to increase human health span. The transaction represents a combined pro forma equity valuation of approximately US$236.2 million, assuming no redemptions by Denali’s public shareholders. Longevity has entered into Contribution and Exchange Agreements with Cerevast Medical, Inc., Aegeria Soft Tissue, LLC, and Novokera, LLC (collectively, the “targets”), pursuant to which, immediately prior to the closing of the proposed transaction Longevity will acquire all of the issued and outstanding equity securities of each of the targets in exchange for shares of common stock of Longevity. Upon the closing of the transaction, the combined company will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq under the ticker symbol LBIO.

The Sidley team is being led by Joshua DuClos (Private Equity) and David Ni (Capital Markets), as well as senior managing associates Jocelyne E. Kelly (M&A) and John Stribling (Capital Markets). The team also includes Courtney Luster, Gabriella Tang, and Jessica Li (M&A); Diahndra Burman (Capital Markets); Jim Lowe and Edward W. Sharon (Antitrust/Competition); Stacy Crosnicker and Malaz K. Moustafa (Employee Benefits and Executive Compensation); Austin Jacobs (Capital Markets); Torrey Cope and Julea Lipiz (Food, Drug and Medical Device); Donielle McCutcheon and Taylor Andelman (Healthcare); Sona De (IP Litigation); Cathryn Le Regulski (Labor and Employment); Angela T. Richards (Tax); and Josh Hofheimer and Cassidy Pomeroy-Carter (Technology and Life Sciences Transactions).~~Sidley is representing Denali Capital Acquisition Corp. (Denali) (NASDAQ: DECA), a publicly traded special purpose acquisition company, in its pending business combination with Longevity Biomedical, Inc. (Longevity), a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring, and digital health solutions to increase human health span. The transaction represents a combined pro forma equity valuation of approximately US$236.2 million, assuming no redemptions by Denali’s public shareholders. Longevity has entered into Contribution and Exchange Agreements with Cerevast Medical, Inc., Aegeria Soft Tissue, LLC, and Novokera, LLC (collectively, the “targets”), pursuant to which, immediately prior to the closing of the proposed transaction Longevity will acquire all of the issued and outstanding equity securities of each of the targets in exchange for shares of common stock of Longevity. Upon the closing of the transaction, the combined company will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq under the ticker symbol LBIO.

The Sidley team is being led by Joshua DuClos (Private Equity) and David Ni (Capital Markets), as well as senior managing associates Jocelyne E. Kelly (M&A) and John Stribling (Capital Markets). The team also includes Courtney Luster, Gabriella Tang, and Jessica Li (M&A); Diahndra Burman (Capital Markets); Jim Lowe and Edward W. Sharon (Antitrust/Competition); Stacy Crosnicker and Malaz K. Moustafa (Employee Benefits and Executive Compensation); Austin Jacobs (Capital Markets); Torrey Cope and Julea Lipiz (Food, Drug and Medical Device); Donielle McCutcheon and Taylor Andelman (Healthcare); Sona De (IP Litigation); Cathryn Le Regulski (Labor and Employment); Angela T. Richards (Tax); and Josh Hofheimer and Cassidy Pomeroy-Carter (Technology and Life Sciences Transactions).